Ongoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence. Rapid Review
Gov't Doc #
MetadataShow full item record
The vast amount of data generated by clinical studies of potential therapeutic options for COVID-19 presents important challenges. This new information must be interpreted quickly so that prescribers can make optimal treatment decisions with as little harm to patients as possible, and so that medicines manufacturers can scale-up production rapidly and bolster their supply chains. Interpreting new data quickly will save lives by ensuring that reportedly successful drugs can be administered to as many patients as possible as quickly as possible. The eighteenth edition of this database of evidence on potential therapeutic options for COVID-19 examines 88 therapeutic options. This information will help investigators, policy makers, and prescribers navigate the flood of relevant data to ensure that management of COVID-19, at both individual and population levels, is based on the best available knowledge. This resource will be continually updated as more research is released into the public space.
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Showing items related by title, author, creator and subject.
Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews, 16 June 2020 Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (Washington, D.C., PAHO, 2020-06-16)Take home message thus far: • We examined 24 therapeutic options thus far; currently, there is no evidence of any important benefit from any therapeutic option (though remdesivir is revealing promise as one option based ...
Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review, 8 September 2020 Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (Washington, D.C., PAHO, 2020-09-11)More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. In this review, we have examined 40 therapeutic options. The Pan American Health Organization (PAHO) is ...
Regulatory considerations on authorization of the use of convalescent plasma (PC) to address the COVID-19 emergency, 22 April 2020 Pan American Health Organization; Health Emergencies (PHE) (Washington, D.C., PAHO, 2020-04-22)Since the last century, passive immunization has been used for the prevention and treatment of some human infectious diseases. The serum of convalescent patients is the treatment of choice in cases of Argentine Hemorrhagic ...